Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 34: 1681-1688, 1988;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ehrlich, P. H.
Right arrow Articles by Ostberg, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ehrlich, P. H.
Right arrow Articles by Ostberg, L.

Clinical Chemistry, Vol 34, 1681-1688, Copyright © 1988 by American Association for Clinical Chemistry

Human and primate monoclonal antibodies for in vivo therapy

PH Ehrlich, ZA Moustafa, JC Justice, KE Harfeldt, IK Gadi, LJ Sciorra, FP Uhl, C Isaacson and L Ostberg
Sandoz Research Institute, Sandoz Pharmaceuticals Corp., E. Hanover, NJ 07936.

Human monoclonal antibodies, owing to their decreased immunogenicity, are expected to be an improvement over mouse monoclonal antibodies for in vivo therapy. Human and primate monoclonal antibodies are best produced with a human x mouse heteromyeloma. Several human chromosomes are stable in the human x (human x mouse) hybrids. Chimpanzee anti- digoxin monoclonal antibodies were prepared and characterized. Because they are structurally very similar to human antibodies, they should be well tolerated in humans. The anti-digoxin antibodies can be used for therapy of extreme overdoses or as an in vivo diagnostic tool for slight overdoses. Because the advantage of using human monoclonal antibodies is their lack of immunogenicity, preparation of the antibody must be scrupulous so as not to introduce extraneous immunogens. Analysis to ensure the purity of the preparation can be complicated by the presence of high concentrations of the antibody and the low levels of contamination that must be detected. We describe a Western blot assay for Protein A that is sensitive even in the presence of human IgG.


The following articles in journals at HighWire Press have cited this article:


Home page
 J. Virol.Home page
D. J. Schofield, J. Glamann, S. U. Emerson, and R. H. Purcell
Identification by Phage Display and Characterization of Two Neutralizing Chimpanzee Monoclonal Antibodies to the Hepatitis E Virus Capsid Protein
J. Virol., June 15, 2000; 74(12): 5548 - 5555.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
W. J. Ball Jr., R. Kasturi, P. Dey, M. Tabet, S. O'Donnell, D. Hudson, and D. Fishwild
Isolation and Characterization of Human Monoclonal Antibodies to Digoxin
J. Immunol., August 15, 1999; 163(4): 2291 - 2298.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the American Association for Clinical Chemistry.